Table 1 Baseline characteristics and HER2 positivity of patients with MIBC
HER2 IHC expression | Total | Negative (0/1 +) | Positive (2 + /3 +) | P |
|---|---|---|---|---|
N (%) | 217(100%) | 92(42.4%) | 125(57.6%) | Â |
Gender | Â | Â | Â | 0.572 |
 Male | 173(79.7%) | 75(34.6%) | 98(45.2%) |  |
 Female | 44(20.3%) | 17(7.8%) | 27(12.4%) |  |
Tumor size (cm) |  |  |  |  < 0.001 |
 ≤ 3 | 125(57.6%) | 73(33.6%) | 52(24.0%) |  |
 > 3 | 92(42.4%) | 19(8.8%) | 73(33.6%) |  |
Single or multiple |  |  |  |  < 0.001 |
 Single | 130(59.9%) | 74(34.1%) | 56(25.8%) |  |
 Multiple | 87(40.1%) | 18(8.3%) | 69(31.8%) |  |
Pathological grades |  |  |  |  < 0.001 |
 Low grade | 73(33.6%) | 44(20.3%) | 29(13.4%) |  |
 High grade | 144(66.4%) | 48(22.1%) | 96(44.2%) |  |
Clinical stages |  |  |  |  < 0.001 |
 T2 | 117(53.9%) | 69(31.8%) | 48(22.1%) |  |
 T3 | 100(46.1%) | 23(10.6%) | 77(35.5%) |  |
Pelvic lymph nodes | Â | Â | Â | 0.011 |
 Yes | 29(13.4%) | 6(2.8%) | 23(10.6%) |  |
 No | 188(86.6%) | 86(39.6%) | 102(47.0%) |  |